AF Symposium 2024 Late-Breaking Science Collection
Published: 19 February 2024
-
Views:
1692
-
Likes:
7
-
Views:
1692
-
Likes:
7
-
Up Next -
9m 49sPart 2 | Session 4 aMAZE CAP: LAA Exclusion in Addition to PVI for Non-paroxysmal AFIB -
5m 41sPart 2 | Session 5 EMERGE LAA Post-Approval: Amulet LAA Occluder in US
-
7m 33sPart 1 3 Studies that Will Change Your Practice with Prof Angelo Auricchio Angelo Auricchio
-
2m 9sPart 2 | Session 1 MANIFEST-PF: Impact of LAPW Ablation During PFA for Persistent AF Mohit K Turagam
-
4m 16sPart 2 | Session 2 Long-Term Effects of Pulsed Field Ablation on Coronary Arteries Yury Malyshev
Overview
Short, accessible Expert Interviews were conducted with investigators focusing on study design, key results and applicability of the latest data.
More from this programme
Part 1
Highlights
Part 2
Expert Interviews
About the episode
AF Symposium 2024 — Dr Emile Daoud (Chief Medical Officer of S4 Medical) joins us to talk about the data from the EASY AF study (NCT04659213).
This randomized, controlled study investigated the use of an esophageal deviating device versus no device. The study showed that the use of the esophageal deviating device (S4 Medical) resulted in a significantly lower rate of ablation-related esophageal lesions compared to the control group (5.7% vs. 35.4%).
- What are some of the unmet needs in AF?
- Can you tell us about the esolution device?
- What was the study design, eligibility criteria, and outcome measures?
- What are the key findings?
- What are the take-home messages for practice? What are the next steps?
Videography: David Ramsey, William Cadden, Brad Wilson, Oliver Miles
Recorded on-site at AF Symposium 2024, Boston.
Comments